Description PI3 Kinase is an oncogene that is commonly mutated in cancer. The PI3K/Akt/mTOR pathway regulates cell growth and survival.

Development Status Phase I clinical trials for metastatic breast cancer and metastatic non-small cell lung cancer are ongoing evaluating GDC-0941 in combination with targeted medicines, such as Avastin® (bevacizumab) (plus chemotherapy) and Tarceva® (erlotinib); and in combination with an investigational targeted agent, T-DM1.

This molecule was discovered by Piramed Ltd. which was acquired by F. Hoffmann-La Roche.

For Avastin full prescribing information, including Boxed WARNINGS and additional important safety information, please visit http://www.avastin.com.

For Tarceva full prescribing information, including additional important safety information, please visit http://www.tarceva.com or call 1-877-TARCEVA.

Additional Information on Clinical Trials For inquiries about our clinical trials, please submit a request through our information request form or call (888) 662-6728.

National Institutes of Health Website: www.clinicaltrials.gov

February 2010